Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05873686 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

A Phase 1 study of Advanced Solid Tumor and Mesothelioma, sponsored by Nuvectis Pharma.

Recruiting
Registry status
Phase 1
Development phase
140
Enrollment target
12
Study locations

NCT05873686 is a Phase 1 study of Advanced Solid Tumor and Mesothelioma that is actively recruiting participants, run by Nuvectis Pharma. The registered enrollment target is 140 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% lower). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05873686, a Phase 1 study of Advanced Solid Tumor and Mesothelioma, is actively recruiting participants, sponsored by Nuvectis Pharma.

RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
12
Study locations

Study Summary

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Conditions Studied

Advanced Solid Tumor Mesothelioma Renal Cancer NSCLC (Non-small Cell Lung Cancer) Non-Small Cell Squamous Lung Cancer Non-small Cell Lung Adenocarcinoma

Interventions

  • DRUG NXP900

Study Locations (12)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology Houston - Houston
  • NEXT Oncology Dallas - Irving

Other

  • Western General Hospital - NHS Lothian - Edinburgh
  • The Royal Marsden NHS Foundation and Trust - London

Arizona

  • Mayo Clinic - Phoenix

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Florida

  • Mayo Clinic - Jacksonville

Illinois

  • University of Chicago - Chicago

Minnesota

  • Mayo Clinic Rochester - Rochester

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-10-26
Est. Completion 2027-07
Phase Phase 1

Sponsor

Nuvectis Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05873686

The ClinicalTrials.gov registry entry for NCT05873686 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% lower). The listed sponsor is Nuvectis Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which NXP900 is the first listed.

NCT05873686 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Texas, Other, Arizona.

Frequently Asked Questions

What is clinical trial NCT05873686 about?

NCT05873686 is a clinical study titled "A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers". This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterat...

What is the current status of trial NCT05873686?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-10-26. Estimated completion is 2027-07.

What conditions does trial NCT05873686 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Mesothelioma, Renal Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Squamous Lung Cancer.

What interventions are being tested in trial NCT05873686?

The interventions under investigation include: NXP900 (DRUG).

Who is sponsoring clinical trial NCT05873686?

This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05873686 being conducted?

This trial has 12 study locations across Arizona, Colorado, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Mesothelioma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.